The drug lenalidomide, marketed as Revlimid, can extend the lives of patients with an aggressive cancer of the bone marrow by up to three years. But draft guidance from the National Institute of Health and Clinical Excellence has said it is not cost effective and the estimate of three years of extra life was disputed.
